✨ Free AI Report
AstraZeneca PLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research AstraZeneca PLC
Company Research

AstraZeneca PLC: Business Overview, Financials & Competitive Analysis

AstraZeneca PLC scores 8/10 on the AskCyborg Cyborg Score (Strong). Growth-driven biotech leader with differentiated oncology franchise pursuing transformative expansion into metabolic health at scale. AstraZeneca has been one of the top-performing large-cap pharmaceutical stocks globally over the last decade. Over 70% of covering analysts maintain a "Buy" or "Overweight" rating as of February 2026. However, execution risk remains given.

What is AstraZeneca PLC's industry? AstraZeneca PLC (astrazeneca.com) operates in Biopharmaceuticals - Oncology & Metabolic Diseases. AskCyborg classifies AstraZeneca PLC under Biopharmaceuticals - Oncology & Metabolic Diseases in its company registry.

AstraZeneca has transformed itself from a struggling mid-tier player a decade ago into a global oncology and rare-disease juggernaut. The company is aggressively pivoting into the obesity and weight-loss market with a...

8/ 10Strong

Cyborg Score thesis

Growth-driven biotech leader with differentiated oncology franchise pursuing transformative expansion into metabolic health at...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Oncology & Metabolic Diseases
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest AstraZeneca PLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for AstraZeneca PLC

AskCyborg analysts argue the bull and bear cases for AstraZeneca PLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
AstraZeneca PLC OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

AstraZeneca PLC Overview

Pro stress-test →

AstraZeneca has transformed itself from a struggling mid-tier player a decade ago into a global oncology and rare-disease juggernaut. The company is aggressively pivoting into the obesity and weight-loss market with a bold target of reaching $80 billion in annual revenue by 2030.

Strategic Profile

Pro stress-test →

AstraZeneca's leadership in antibody-drug conjugates (ADCs) gives it a distinct advantage in specific cancer markets where traditional immunotherapies are less effective. The company is positioning itself as the leader in "next-generation" metabolic health, focusing on weight loss that preserves muscle mass and provides superior cardiovascular protection.

Competitive Landscape

Pro stress-test →

In oncology, Merck & Co. is the primary rival with Keytruda as the world's top-selling drug, but AstraZeneca's ADC leadership provides distinct advantages in specific niche cancer markets. In obesity, AstraZeneca trails Novo Nordisk and Eli Lilly but is differentiating through next-generation metabolic health positioning.

Industry Context

AstraZeneca PLC operates in Biopharmaceuticals - Oncology & Metabolic Diseases.

Key facts

Founded: 1999 · Headquarters: Cambridge, UK · Revenue: $58.74B

What the analysts stress-tested

The top findings that survived the multi-agent debate for AstraZeneca PLC.

  • The company's oral GLP-1 candidate, ECC5004, entered Phase 3 trials in early 2026, promising a more convenient alternative to injectable competitors.
  • AstraZeneca expects more than 20 Phase 3 trial readouts in 2026 with more than 100 Phase 3 studies ongoing.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026AstraZeneca implemented its harmonised listing structure with ordinary shares now listed directly on the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange.
  • February 2026ECC5004 oral GLP-1 candidate entered Phase 3 trials.
  • +1 moreTrack every material event for AstraZeneca PLC as it happens. Explore monitoring →
Get alerted when AstraZeneca PLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KeytrudaLeading oncology immunotherapy→Ozempic/MounjaroObesity and metabolic disease leader→Obesity portfolioGLP-1 metabolic diseases→Oncology portfolioDiversified pharma competitor→

Compare AstraZeneca PLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

AstraZeneca PLC operates in Biopharmaceuticals - Oncology & Metabolic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Oncology & Metabolic Diseases research →
NEW · MCP server

Ask your AI assistant about AstraZeneca PLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare AstraZeneca PLC and its top competitor on Cyborg Score”
“What did AstraZeneca PLC do this quarter?”
“Is AstraZeneca PLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does AstraZeneca PLC do?+
AstraZeneca has transformed itself from a struggling mid-tier player a decade ago into a global oncology and rare-disease juggernaut. The company is aggressively pivoting into the obesity and weight-loss market with a...
What is AstraZeneca PLC's Cyborg Score?+
AstraZeneca PLC has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are AstraZeneca PLC's main competitors?+
Named competitors include Keytruda, Ozempic/Mounjaro, Obesity portfolio, Oncology portfolio. The full competitive landscape is in the AskCyborg report.
How can I get the full AstraZeneca PLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the AstraZeneca PLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track AstraZeneca PLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Oncology & Metabolic Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8AstraZeneca PLC